

Appendix 1: Candidates for the Board of Directors

*Listed companies



Bo Jesper Hansen Deputy Chairman

Member since: 2010 (Deputy Chairman since 2017)

Born in: 1958

Nationality: Danish

Committees: Remuneration Committee (Chairman), Nomination Committee, Audit Committee

Special competences

Dr. Hansen's extensive experience in orphan drugs, both from the operations and supervisory point of view and his broad and current know-how of the biotechnology environment makes him a qualified member of the Board of Directors.

Other management duties

Bo Jesper Hansen is currently Chairman of the Board of Directors of Laborie Inc., Innoventa Medica ApS, and Karo Pharma AB and a member of the Board of Directors of Ascelia Pharma AB and Reapplix A/S.

Previous experience

Bo Jesper Hansen has previously been Chairman of the Board of Directors and a member of the Executive Management of Swedish Orphan Biovitrum AB (publ), Chairman of the Board of Directors of Ablynx NV, Topotarget A/S (publ), Karolinska Development AB (publ) and a member of the Board of Directors of Newron Pharmaceuticals SpA, CMC Sweden AB, Hyperion Therapeutics Inc. (publ), Gambro AB, Inspyr Inc. (publ), Zymenex Holding A/S, Zymenex A/S, ACE Bioscience A/S, Mipsalus Holding ApS, MipSalus ApS, Azanta A/S, and Reapplix A/S.

Educational background

Bo Jesper Hansen holds an MD and PhD in Medicine from the University of Copenhagen.

Independence

Bo Jesper Hansen is considered as independent.



Anders Fink Vadsholt Chief Executive Officer and Chief Financial Officer

New Board candidate

Born in: 1969

Nationality: Danish

Special competences

Anders Fink Vadsholt has 25 years' experience from corporate finance, venture capital and the biotech industry and has been involved in a number of capital market transactions. He joined Orphazyme A/S in 2016.

Other management duties

Anders Fink Vadsholt is currently the Chief Executive Officer and Chief Financial Officer of Orphazyme A/S..

Previous experience

Anders Fink Vadsholt has previous experience from positions at BankInvest Biomedical Venture, Topotarget A/S, and Carnegie Investment Bank.

Educational background

Anders Fink Vadsholt holds an MSc in Commercial Law and Economics from Copenhagen Business School and a MBA from Melbourne University.

Independence

Anders Fink Vadsholt is not considered as independent, as he is currently the Chief Executive Officer and Chief Financial Officer of Orphazyme A/S.



John Sommer Schmidt

New Board candidate

Born in: 1973

Nationality: Danish

Special competences

John Sommer Schmidt has extensive knowledge of and hands-on experience with all aspects of Danish Bankruptcy and reconstruction law and also acts as liquidator, reconstruction administrator and trustee. Over the years, John Sommer Schmidt has administered some of the largest and most complex bankruptcy estates in Denmark, including bankruptcy estates with very complex issues of international/cross-border nature.

Other management duties

John Sommer Schmidt has been a partner at Gorrissen Federspiel since 2011 and heads the firm's insolvency and restructuring team, furthermore he is a member of the Board of Directors at the Association of Danish Insolvency Lawyers.

Previous experience

John Sommer Schmidt has previous experience from positions at OWAT ApS, Rederiet O.W. Baltic A/S, Rederiet Atlantic A/S, Rederiet Atlantic A/S,, Rederiet Copenhagen A/S, Rederiet Oxana A/S,, Rederiet Pacific A/S, Rederiet Scandinavia A/S, Rederiet Aalborg A/S.

Educational background

John Sommer Schmidt holds a Law degree from Aarhus University, a LL.M. from University of California, Los Angeles School of Law, and a B.Sc. (jur.) from Aarhus School of Business 1998. Furthermore he was appointed lawyer by the Danish Bar and law Society in 2004.

Independence

John Sommer Schmidt is considered as independent.